r-phase12designs

Provides a comprehensive set of tools to simulate, evaluate, and compare model-assisted designs for early-phase (Phase I/II) clinical trials, including: - BOIN12 (Bayesian optimal interval phase 1/11 trial design; Lin et al. (2020) <doi:10.1200/PO.20.00257>), - BOIN-ET (Takeda, K., Taguri, M., & Morita, S. (2018) <doi:10.1002/pst.1864>), - EffTox (Thall, P. F., & Cook, J. D. (2004) <doi:10.1111/j.0006-341X.2004.00218.x>), - Ji3+3 (Joint i3+3 design; Lin, X., & Ji, Y. (2020) <doi:10.1080/10543406.2020.1818250>), - PRINTE (probability intervals of toxicity and efficacy design; Lin, X., & Ji, Y. (2021) <doi:10.1177/0962280220977009>), - STEIN (simple toxicity and efficacy interval design; Lin, R., & Yin, G. (2017) <doi:10.1002/sim.7428>), - TEPI (toxicity and efficacy probability interval design; Li, D. H., Whitmore, J. B., Guo, W., & Ji, Y. (2017) <doi:10.1158/1078-0432.CCR-16-1125>), - uTPI (utility-based toxicity Probability interval design; Shi, H., Lin, R., & Lin, X. (2024) <doi:10.1002/sim.8922>). Includes flexible simulation parameters that allow researchers to efficiently compute operating characteristics under various fixed and random trial scenarios and export the results.